MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Solifenacin Succinate

CAS No. : 242478-38-2

MCE 国际站：Solifenacin Succinate

产品活性：Solifenacin Succinate (YM905) 是毒蕈碱受体 (muscarinic receptor) 拮抗剂，对 M₁，M₂ 和 M₃ 受体的 pK_i 值分别为 7.6、6.9 和 8.0。

研究领域：GPCR/G Protein  |  Neuronal Signaling

作用靶点：mAChR

In Vitro: Solifenacin Succinate (YM905) is a novel muscarinic receptor antagonist with pK_is of 7.6±0.056, 6.9±0.034 and 8.0±0.021 for M1, M2 and M3 receptors, respectively. In murine submandibular gland cells, the antagonistic effects of 100 nM Solifenacin Succinate and oxybutynin on Ca²⁺ mobilization evoked by varying doses of carbachol (CCh) are examined. Solifenacin Succinate does not shift the CCh dose-activation curve in a parallel manner whereas oxybutynin shows insurmountable antagonism. The pK_b values are obtained as 7.4±0.17 for Solifenacin Succinate and 8.8±0.21 for oxybutynin.

In Vivo: Solifenacin Succinate (YM905) reduces bladder responses by 40% at a dose of 210 nmol/kg (0.1 mg/kg) and abolishes them at 2100 nmol/kg (1 mg/kg). In contrast, its inhibitory effects on salivary and cardiac responses are only slight at 630 nmol/kg (0.3 mg/kg), and reach 66% and 49%, respectively, at 2100 nmol/kg (1 mg/kg). At doses of 63 and 210 nmol/kg (0.03 and 0.1 mg/kg), Solifenacin Succinate slightly increases saliva secretion. Solifenacin Succinate (0.01 to 0.3 mg/kg i.v.) dose-dependently increases bladder capacity and voided volume at doses of 0.03 mg/kg i.v. or more, but does not affect residual volume or micturition pressure at any dose tested.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  Neuronal Signaling Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  CNS-Penetrant Compound Library  |  Drug Repurposing Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  Neurotransmitter Receptor Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Parkinson's Disease Compound Library  |  Neurodegenerative Disease-related Compound Library  |  Mechanoreceptors Compound Library  |  Rare Diseases Drug Library  |  FDA-Approved Anticancer Drug Library  |  Anti-Prostate Cancer Compound Library  |  Heterocyclic Compound Library  |  Off-patent Drug Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  VU0357017 hydrochloride  |  5-Hydroxy tryptophol β-D-glucuronide-d₄  |  TBPB  |  Tropicamide-d₃  |  Imidafenacin  |  (±)-Muscarine chloride  |  mAChR-IN-1 hydrochloride  |  Scopolamine butylbromide  |  Navafenterol  |  Fustin  |  Penehyclidine  |  VU 0255035  |  DREADD agonist 21  |  Umeclidinium-d₅ bromide  |  Cevimeline  |  Methacholine bromide  |  Iperoxo  |  VU0467485  |  M4 mAChR agonist-1  |  Clozapine  |  Brompheniramine maleate  |  Umeclidinium bromide  |  Zamifenacin fumarate  |  Parapenzolate bromide  |  (-)-Cevimeline hydrochloride hemihydrate  |  LY2119620  |  Milameline hydrochloride  |  β2AR/M-receptor agonist-2

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。